Effects of panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus

Chinese Journal of Integrative Medicine

Volumn 17, Issue 8, 2011, Pages 612-615

  Tu, Qing Nian ^a   Dong, Hui ^a   Lu, Fu Er ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Diabetic nephropathy; Panax notoginoside; Type 1 diabetes

Indexed keywords

ALBUMIN; CAPTOPRIL; CREATININE; HERBACEOUS AGENT; OSTEOGENIC PROTEIN 1; PANAX NOTOGINOSIDE; STREPTOZOCIN; UNCLASSIFIED DRUG; VASCULOTROPIN; PLANT EXTRACT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MEGADOSE; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; BODY WEIGHT; CHEMISTRY; HYPERTROPHY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; KIDNEY FUNCTION TEST; METABOLISM; PANAX; PATHOLOGY; PATHOPHYSIOLOGY; PHYTOTHERAPY; PROTEINURIA; WISTAR RAT;

ANIMALS; BODY WEIGHT; BONE MORPHOGENETIC PROTEIN 7; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FUNCTION TESTS; MALE; PANAX; PHYTOTHERAPY; PLANT EXTRACTS; PROTEINURIA; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855175926     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-011-0825-9     Document Type: Article

References (12)

1. Kreisberg JI, Ayo SH. The glomerular mesangium in diabetes mellitus. Kidney Int 1993;43:109-113.
2. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999;56:1627-1637.
3. Chen S, Ziyadeh FN. Vascular endothelial growth factor and diabetic nephropathy. Curr Diabete Rep 2008;8:470-476.
4. Zhang Y, Zhang Q. Bone morphogentic protein-7 and gremlin: new emerging therapeutic targets for diabetic nephropathy. Biochem Biophys Res Commun 2009;383:1-3.
5. Gao HL, Liu FY, Xia ZL. Theoretical study and application of experimental diabetic animal models. Chin J Rehabil (Chin) 2005;9:210-212.
6. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999;48:2229-2239.
7. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993-1000.
8. Flyvbjerg A, Dagnaes-Hansen F, de Vriese AS, Schrijvers. BF, Tilton RG, Rasch R. Amelioration of long term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002;51:3090-3094.
9. Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003;63:2037-2049.
10. Wang S, de Caestecker M, Kopp J, Mitu G, Lapage J, Hirschberg R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006;17:2504-2512.
11. Dong XL, Niu SY, Xu HB, Han MY. Effects of hyperbaric oxygenation associated with Panax notoginseng saponins therapy on hemorrhology indexes in patients with ischemic cerebrovascular disease. Chin J Rehabil (Chin) 2005;9:6-7.
12. Guo M, Liu HY, Chen XW. The mechanisms of progression of renal interstitial fibrosis and the therapeutic effects of Panax notoginoside. Chin J Integr Tradit West Nephrol (Chin) 2007;8:175-178.